new data findings/day
patient tests analyzed
Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.
Join us at an event or attend a webinar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.
Evidence based research, services and advanced software for better decisions.
It’s already happened: Several SARS-CoV-2 variants are upon us, lurking in various populations, br...
How integrative analysis of multi-omics data accelerates biomarker and target discovery in inherited...
Whole-exome sequencing (WES) using next-generation sequencing (NGS) technology is a powerful tool fo...
Next-generation sequencing (NGS) techniques allow high-throughput detection of a vast amount of gene...
Hint: The secret is in the biological context Today's discovery scientists are challenged with iden...
Scale up, quickly and easily: SARS-CoV-2 genomic surveillance data analysis
Reveal the genetic mechanisms of inherited disease
Using the Interactive Filter Cascade in QCI Interpret Translational
Overcoming Challenges in Variant Filtering and Prioritization
The key to target and biomarker discovery
Targeted NGS panels and optimized analysis and interpretation tools.
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development.
Interpretation of gene expression data to tackle inflammatory bowel disease
In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.
Mount Sinai's novel biomarker predicts treatment outcome in ovarian cancer